Key Takeaways
- A pivot year, not yet a breakout: NIP and OTF sales grew 64% to ₹62.4 crore (16.5% of revenue), but EBITDA margin improved only 40 bps to 13.1% as legacy price pressure absorbed the gain.
- The CapEx cycle is done: Gross block has nearly doubled to ~₹340 crore over 2.5–3 years; both new suites are ready, and management says no further major projects will be taken forward.
- Revenue visibility is building, not built: 12 NIP products are in the pipeline, 3 commercial launches are slated for H2 FY27, and MAs are expected to start arriving over the next 3–4 quarters, but exact timing sits with regulators and marketing partners.
- Legacy business was deliberately pruned: The base business declined partly from voluntary removal of low-margin work and partly from an election-year pause in domestic institutional orders, including a specific ₹20 crore Maharashtra government order that did not recur.
- What to watch next quarter: Whether the company provides the quantitative guidance it has deferred to Q1–Q2, any MA approvals that convert the pipeline into commercial supplies, and stabilization of the legacy business at the promised 5–10% growth rate.
The Pivot: NIP/OTF Growth vs. Margin Reality
- NIP/OTF is the growth engine: These two categories together delivered ₹62.4 crore in FY25, 16.5% of total revenue, fuelled by licensing and co-development partnerships, with regulated-market out-licensing income alone contributing ₹9.8 crore.
- Margins have not yet followed: EBITDA margin moved from 12.7% (FY24) to 13.1% (FY25) despite the 64% NIP/OTF jump, because legacy products face price pressure that the new products are only just offsetting. Management calls this a pivot phase and expects margin expansion once the NIP/OTF share rises further, since OpEx and other costs will remain practically the same.
- NIP contribution target: Management expects NIP to reach 30–40% of total revenue in the coming years, and over time NIP plus OTF could go up to 50% of the business.
- EBITDA margin ambition: The company is targeting upper-teens EBITDA margins going forward, though no timeline was committed.
Anwar Daud: "The company is in the stage of a pivot."
Regulatory Pipeline & Commercial Launch Timeline
- Filings completed in FY25: 23 NIP filings for 6 molecules, 17 OTF filings for 5 molecules, and 10 FF filings for 5 molecules across regulated, Pharmerging and rest-of-world markets. In the EU specifically, 5 NIP filings for 4 molecules and 6 OTF filings for 2 molecules were completed, bringing cumulative EU NIP filings to 7.
- MAs received: Azithromycin oral suspension and Dimethyl Fumarate NIP received marketing authorization; a partner secured approval for buprenorphine sublingual film OTF across Europe.
- Near-term revenue visibility: Dimethyl Fumarate and Buprenorphine are expected to generate revenue in FY26 from regulated markets, with revenue anticipated by end of Q3 and Q4. The Neuraxpharm product launch is expected in another 2 quarters.
- FY27 launch window: Three commercial launches are expected in the second half of FY27.
- MA timing dependency: Most products are expected to start receiving MAs in the last quarter or beginning of next year; at least 2–3 MAs are expected in the first quarter of next year. The company expects to grow 25–30% over the next 2–3 years as all MAs arrive over the next 3–4 quarters.
- Regulatory risk acknowledged: Regulatory timelines are not in the company's hands, and launches also depend on marketing partners. Mitigation comes from using multiple partners on a non-exclusive basis and filing dossiers under ZIM's own name to retain MA rights.
Anwar Daud: "In the next 2 years... do you see the company growing? And we said, yes, certainly, because all the MAs are coming in now and coming in the 3 or 4 quarters that we have spoken about."
Legacy Business: The Deliberate Reset
- Why the base declined: The legacy business (ex-NIP/OTF) shrank due to headwinds in the PFI side, currency issues that have now been resolved, and voluntary removal of low-margin business. Domestic revenue fell 17% partly from that voluntary pruning and partly because FY25 was an election year when institutions paused orders, including a specific ₹20 crore Government of Maharashtra order that was not received and did not defer to the next year.
- Stabilization promised: Management expects the legacy business to stabilize at its previous rate and see nominal growth on the same line going forward, with 5–10% growth projected for FY26, though more confident numbers will only be available at the end of the second quarter.
- Dr. Reddy's partnership: Last year was a one-off hiccup because the product launched the year before; that hiccup will not recur next year. The urology NIP product launched in limited states and is now planned for a pan-India rollout, with growth expected.
Capacity, CapEx & the Balance Sheet
- Infrastructure build is complete: A dedicated urology suite for NIP products and a specialized liquid-in-pellet technology suite for high-value OTC products have been completed. Gross block moved from ~₹190 crore to ~₹340 crore over 2.5–3 years.
- No further major CapEx: Management stated explicitly that all major CapEx has been closed, borrowings have been closed, and future spending will only be on upgrades and technology improvements. Capacity utilization is currently very low, and no further capital expenditure will be needed.
- No deleveraging plans: There is no plan to deleverage or add borrowings at this moment.
- Asset turnover will improve with MAs: The fixed asset turnover ratio will improve once marketing authorizations are received and the newly built capacity is utilized.
Anwar Daud: "We are building in CapEx for the future. We know that the products we have developed have potential. We have had early successes in the MAs... our filing strategy is in place, and our partnerships are in place as well."
Geographic & Partnership Expansion
- Middle East push: A strategic collaboration with a local UAE company was signed to scale the Oral Thin Film footprint across the GCC region, and a scientific office was established in the Middle East. A partnership with Globalpharma for the entire Middle East was announced last month.
- Australia subsidiary: ZIMTAS Pty. Limited has filed 2 products (one NIP, one OTF) under ZIM's own name, with MAs belonging to ZIM itself. Regulatory filings for innovative products including OTF and complex products for Europe and the UK are in progress. MAs are expected immediately, and a marketing agreement is being finalized; by Q2 or Q3 the company expects a clear idea of the launch timeline.
- Filing strategy shift: ZIM is now filing and investing in dossiers under its own name so that at the end of the process it holds its own MA, giving it the right to multiply the MA and have multiple partners. This is a key learning from Phase 1 of the NIP strategy.
- Out-licensing partner quality: Out-licensing deals are with companies sized between $350 million and $1.5 billion, which management frames as a signal of confidence in product and dossier quality.
Anwar Daud: "The out-licensing deals are with companies in the size of between $350 million to about $1.5 billion. And they will not sign these agreements unless they are confident of the product as well as the quality of the dossier and the quality of the submission."
R&D & the Next Pipeline
- R&D intensity steady: R&D spend accounted for 8.8% of total operating income in FY25 and is expected to remain around 8.5% on a similar absolute line going forward, sustaining the NIP and NIP 2 pipeline momentum with the same BE and filing budgets.
- Pipeline status: 12 NIP products are in the pipeline; development of 8 is already completed, and the remaining 4 will be finalized and filed through FY26. Work on the second-generation NIP pipeline has already begun, and the next set of NIP products has been selected — these are described as differentiated, more complex, and first-to-file.
- NIP 2 line: The company has started developing its NIP 2 line, which will provide new technology.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Legacy business stabilization | Recover to previous levels, nominal growth of 5–10% | FY26; more confident numbers at end of Q2 FY26 |
| NIP/OTF revenue contribution | 30–40% of total sales | "Coming years" |
| NIP/OTF revenue contribution | Up to 50% of total business | "Over a period of time" |
| EBITDA margin | Upper teens | "Going forward" |
| Revenue growth | 25–30% | Next 2–3 years, contingent on MAs arriving over next 3–4 quarters |
| First sales from new products | Starting to sell | By Q3 FY26 |
| Commercial launches | 3 launches | H2 FY27 |
| Neuraxpharm product launch | Launch | In another 2 quarters |
| Dimethyl Fumarate and Buprenorphine revenue | Revenue from regulated markets | By end of Q3 and Q4 FY26 |
| Remaining NIP pipeline filings | 4 products finalized and filed | Through FY26 |
| Quantitative guidance on NIP/OTF percentage and revenue | Exact guidance provided | After Q2 FY26, once clarity on MAs and marketing partner agreements is available |
| Australia launch clarity | Clear idea of launch | By Q2 or Q3 FY26 |
| CapEx | No further major projects; only upgrades | Ongoing |
| R&D spend | ~8.5% of revenue on similar absolute numbers | Going forward |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Total Operating Income | ₹108.7 crore, +12.9% QoQ and -7.7% YoY |
| EBITDA | ₹16.3 crore, +22.5% QoQ and -5.2% YoY |
| EBITDA margin | 15%, improved from 12.7% in FY24 |
| PAT | ₹4.9 crore, +22.1% QoQ and -39.7% YoY |
| PAT margin | 4.5% |
| Pharmaceutical business revenue | ₹89.1 crore, 82% of total operating income, +20.6% QoQ and -8.8% YoY |
| Nutraceutical business revenue | ₹19.6 crore, 18% of total operating income |
| R&D investment | ₹7.6 crore, 7% of total operating income |
| CapEx | ₹6.5 crore, primarily directed towards infrastructure upgrades and specialized facility enhancement |
| Total Operating Income (FY25) | ₹379 crore, +3.2% YoY |
| EBITDA (FY25) | ₹49.5 crore, +6.4% YoY |
| EBITDA margin (FY25) | 13.1% |
| PAT (FY25) | ₹12.2 crore, PAT margin of 3.2% |
| NIP + OTF sales (FY25) | ₹62.4 crore, 16.5% of total revenue, grew 64% YoY |
| NIP segment contribution (FY25) | ₹43.7 crore |
| OTF contribution (FY25) | ₹18.6 crore |
| Export market contribution (FY25) | ₹312.5 crore, 83% of total operating income |
| Domestic market contribution (FY25) | ₹66.5 crore, 17% of total operating income |
| Annual CapEx (FY25) | ₹36.5 crore |
| R&D spend (FY25) | 8.8% of total operating income |
| NIP filings (FY25) | 23 filings for 6 molecules |
| OTF filings (FY25) | 17 filings for 5 molecules |
| Cumulative EU NIP filings to date | 7 |
| NIP pipeline | 12 products, development of 8 completed |
| Inventory days | 80–81 days, currently on a 100-day cycle, improving to 90 days |
| Net GCA days | 60–63 days |
| Domestic revenue FY24 vs FY25 | ₹64.6 crore in FY24, ₹53.6 crore in FY25, a 17% de-growth |
| Government of Maharashtra order not received in FY25 | ~₹20 crore order deferred due to election year |
| Employee cost expectation FY26 | ₹65–68 crore, expected to stabilize |
| Legacy business growth expectation FY26 | 5%–10% |
| NIP + OTF contribution to total sales expectation | 30%–40% going forward |